ArticleInternational journal of nanomedicine2026
Mitochondria-Targeted MPDA Nanosystem Co-Delivering Evodiamine and IR820 for Chemo-Photothermal Therapy of Hepatocellular Carcinoma.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural Products and Traditional Chinese Medicine in Hepatocellular Carcinoma: From Pharmacological Mechanisms to Clinical Translation.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatocellular carcinoma (HCC) is a highly malignant tumor characterized by considerable heterogeneity, aggressive invasiveness, and a high recurrence rate. Monotherapy often yields limited clinical efficacy, and evodiamine (EVO), a natural alkaloid with promising antitumor activity, is hindered by low bioavailability and potential systemic toxicity. Methods: A mesoporous polydopamine (MPDA)-based theranostic nanosystem was constructed for the co-delivery of EVO and the photothermal agent IR820. To enhance tumor specificity and minimize off-target toxicity, the platform was functionalized with cyclic RGD (cRGD) peptides for active tumor homing and triphenylphosphonium (TPP) for mitochondrial localization. The resulting IR820/EVO@MPDA-TPP/cRGD nanoparticles were characterized for drug loading, photothermal conversion stability, and fluorescence properties, and evaluated for antitumor efficacy and mechanistic actions in vivo. Results: The nanosystem demonstrated high drug loading efficiencies, excellent photothermal conversion stability, and robust near-infrared fluorescence emission suitable for real-time diagnostic tracing. Upon NIR laser irradiation, IR820/EVO@MPDA-TPP/cRGD exhibited potent synergistic anticancer activity and significantly inhibited tumor growth in vivo. Mechanistically, the combined photothermal and chemotherapeutic effects triggered severe mitochondrial dysfunction, leading to the collapse of mitochondrial membrane potential and subsequent release of pro-apoptotic factors. Discussion: The dual-targeting strategy effectively shifted cellular homeostasis toward programmed cell death while simultaneously engaging quality control pathways, underscoring a mitochondria-centered mechanism linking photothermal effect and chemotherapy. Conclusion: IR820/EVO@MPDA-TPP/cRGD represents a dual-targeting theranostic nanoplatform that integrates imaging and chemo-photothermal combination therapy. This strategy offers a promising and clinically relevant approach for advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.